Lefisyo (Levomethadone Hydrochloride)

Levomethadone Hydrochloride acts on the mu‑opioid receptor pathway to provide analgesia and support opioid substitution therapy.

• Pain management: reduces moderate to severe chronic pain when other analgesics are insufficient.
• Opioid dependence treatment: facilitates withdrawal management and maintenance therapy in individuals with opioid use disorder.
• Post‑operative analgesia: provides short‑term pain relief following surgical procedures.

• Levomethadone Hydrochloride binds selectively to mu‑opioid receptors in the central nervous system, acting as a full agonist. This activation inhibits nociceptive neurotransmission, producing analgesia, and also mitigates withdrawal symptoms by substituting for other opioids, thereby stabilizing receptor activity and reducing cravings.

Levomethadone Hydrochloride may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Nausea: mild to moderate stomach upset.
• Constipation: reduced bowel motility.
• Drowsiness: increased sleepiness.
• Dizziness: light‑headed sensation.
• Dry mouth: reduced salivation.
• Sweating: excessive perspiration.

Serious or Rare Side Effects

• Respiratory depression: slowed breathing, potentially life‑threatening.
• Cardiac arrhythmia: irregular heart rhythm, including QT prolongation.
• Severe hypotension: marked drop in blood pressure.
• Seizures: convulsive episodes.
• Allergic reactions: rash, itching, swelling, or anaphylaxis.

When prescribing Levomethadone Hydrochloride, clinicians should consider several safety measures.

• Assess respiratory function: monitor for signs of respiratory depression, especially in opioid‑naïve patients.
• Evaluate cardiac risk: obtain baseline ECG to detect QT interval prolongation.
• Review concomitant CNS depressants: avoid or adjust doses when combined with benzodiazepines or alcohol.
• Monitor liver function: adjust dosing in hepatic impairment.
• Educate patients on dependence: discuss risks of tolerance and addiction.
• Store at ambient temperature: keep below 25 °C in the original container, protect from moisture and direct sunlight.

Levomethadone Hydrochloride can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Other opioids: additive respiratory depression.
• CNS depressants (e.g., benzodiazepines, barbiturates): heightened sedation and respiratory risk.
• QT‑prolonging agents (e.g., certain antiarrhythmics, macrolide antibiotics): increased risk of cardiac arrhythmia.

Moderate Interactions (Monitor Closely):\n- CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): may raise levomethadone plasma levels.

• CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce drug concentration.
• Anticholinergic drugs: may exacerbate constipation.